The inflammatory response is a body reaction to infection, irritation or tissue injury.
Inflammation is a three-step process (onset, development, resolution) regulated by various biochemical molecules (lipidic mediators, chemokines, cytokines) and the mobilization of different cell types.
Those events lead to the mobilization of the innate and adaptive immunity system as response against the origins of the inflammatory disorders.
It is commonly admitted that the inflammatory response switches off when the pro-inflammatory mediators are metabolized into inactive compounds.
Non Steroidal Anti Inflammatory Drugs (NSAIDs) act this way: they inhibit the inflammatory process by inhibiting cyclooxygenases and thus the synthesis of PGE2. They show a strong efficiency for the treatment of acute inflammation and a weaker efficiency for the treatment of chronic inflammation. Furthermore, unpleasant side effects have been reported.
Considering recent concepts, it may be possible to envision new strategies in order to control inflammation.
In contrast to the classical hypothesis, it has been established that the immune system is under the control of endogenous pathways to get back to homeostasis. Those pathways, called resolving pathways, are essential for the end of the inflammatory process. They are involved in the cure of the inflamed tissue, which will completely recover its former architecture and thus its functionality.
Ambiotis develops R&D programs to investigate the naturally occurring mechanisms involved in the end of the inflammatory process and based on: